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Abstract
Most potent therapeutics are unable to cross the blood-brain barrier following systemic 
administration, which necessitates the development of unconventional, clinically applicable drug 
delivery systems. With the given challenges, biologically active vehicles are crucial to 
accomplishing this task. We now report a new method for drug delivery that utilizes living cells as 
vehicles for drug carriage across the blood brain barrier. Cellular backpacks, 7–10 µm diameter 
polymer patches of a few hundred nanometers in thickness, are a potentially interesting approach, 
because they can act as drug depots that travel with the cell-carrier, without being phagocytized. 
Backpacks loaded with a potent antioxidant, catalase, were attached to autologous macrophages 
and systemically administered into mice with brain inflammation. Using inflammatory response 
cells enabled targeted drug transport to the inflamed brain. Furthermore, catalase-loaded 
backpacks demonstrated potent therapeutic effects deactivating free radicals released by activated 
microglia in vitro. This approach for drug carriage and release can accelerate the development of 
new drug formulations for all the neurodegenerative disorders.
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1. Introduction
The delivery of therapeutics across the blood brain barrier (BBB) has been extremely 
challenging and is currently a major impediment for the treatment of diseases in the brain. 
Recently, living cells have been investigated as carriers for actively targeted drug delivery, 
which has opened new therapeutic avenues within the central nervous system (CNS) [1]. For 
this strategy to be successful, the efficient penetration across the BBB by cell-carriers is 
crucial for the success of these cell-based formulations. Some cell types are naturally 
capable of crossing the BBB, such as leukocytes (neutrophils and monocytes), which can 
traverse the endothelial wall due to increased margination and extravasation [2] when the 
BBB breaks down during inflammation [3–6]. These cells appear to traffic primarily 
between adjacent endothelial cells through the transient opening of tight junctions [7,8], and 
utilizing diapedesis and chemotaxis [9]. Because of their natural recruitment across the BBB 
during inflammation, immune cells are an ideal candidate as cellular vehicles for drug 
delivery.
For maximal efficacy, immune cells should carry therapeutically significant quantities of 
drug. Traditional strategies often result in poor drug loadings because they are sequestered 
within the phagosome of macrophages, which potentially degrades the drug and reduces the 
release rates. Furthermore, accumulated drugs, especially antineoplastic agents, may degrade 
the survival or migration of the cell-carrier [10], which has created a bottleneck for cell-
based therapy. In addition, the small size of payload materials traversing the BBB with cell 
carriers can limit the amount delivered, with 100–200 nm particles currently being the 
largest [11]. To circumvent these limitations, cellular backpacks, micron-scale patches of a 
few hundred nanometers in thickness, were fabricated by layer-by-layer (LbL) assembly to 
be attached to the surface of cell-carriers [12–14]. Due to their shape, size and composition, 
cellular backpacks are not engulfed by macrophages, making them an attractive strategy that 
sequesters the cargo outside the cells to protect both the cell and the drug from degradation. 
Recent work has demonstrated that backpack-monocyte conjugates migrate and accumulate 
in inflamed tissue sites (e.g. lungs and skin) [15]. These cellular backpacks can be designed 
to carry toxic loads of a potent anticancer drug without affecting cell's natural functions [16]. 
Furthermore, cell backpacks loaded with catalase have shown antioxidant properties in vitro 
[17].
In this work, we introduce a new method that allows for noninvasive, safe and efficient 
access to most secluded sites in the brain. This strategy can be used for treatment of various 
neurodegenerative disorders, infectious diseases, and other types of brain and cellular 
injuries. We demonstrate that backpacks loaded with catalase can be attached to 
macrophages and transported across the BBB in a mouse model of lipopolysaccharide 
(LPS)-induced encephalitis. This indicates that engaging natural immune cells such as 
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monocyte-macrophages as drug carriers is a potentially new strategy for treating a range of 
neuroinflammatory and neurodegenerative diseases.
2. Results
2.1. Cell backpacks
Backpacks were constructed by a combination of photolithography and layer-by-layer (LbL) 
assembly [14], which resulted in disc-shaped polymer patches 7 µm in diameter. As shown 
in Fig. 1, the cell backpacks were initially fabricated by deposition of various material 
regions, serially, onto a glass microscope slide. At the interface between the glass slide and 
the assembled multilayer construct is a “release region” which can dissolve upon incubation 
with the sugar, melibiose. We had previously developed this as a simple and benign means to 
releasing backpacks from their substrates [18]. Atop this sacrificial film, we deposited a 
“magnetic region” to aid in purification of cell backpacks, confer film rigidity and 
potentially serve as an imaging agent [19–22]. Then we deposited a “payload region” that, in 
this case, contains catalase, a potent anti-oxidant (More details about catalase payload region 
can be found in Supplemental Fig. 1). Finally, the top layer is composed of a “cell 
attachment region”, which contains antibodies that enable the backpacks to specifically 
attach to desired cell-types. In this instance, we attached macrophage-targeting polyclonal 
antibodies through avidin-biotin links. Catalase-loaded backpacks could withstand the 
fabrication processing (See more details on Supplemental Fig. 2).
2.2. Ability for backpacks to cross the BBB in vitro
Cell backpacks were attached to macrophages as follows. Fluorescently-labeled DiO-
macrophages (green, 2 × 106 cells/ml) were pipetted onto the surfaces of glass slides with 
fabricated cell backpacks, which were functionalized with NeutrAvidin Dylight 550 (red). 
After a brief incubation, macrophages adhered to the backpacks via CD11b antibody 
attachment, and the glass slides were thrice washed with media to remove non-adhered cells. 
(See online methods for more details; Supplemental Fig. 3). To detach the macrophage-
backpack conjugates, the glass slides were incubated with 1 mL of 100 mM melibiose in 
PBS for 1 h at 37 °C18. The remaining weakly adhered macrophage-backpack conjugates 
were removed with a cell scraper and re-suspended into saline-buffered solution.
Fig. 2 shows microscope images of macrophages with attached backpacks. For this purpose, 
macrophages were labeled with a fluorescent dye DiO (green) and pipetted onto the surface 
of the glass slide with backpacks stained with Neutravidin Dylight 550 (red). Non-adhered 
cells were removed by rinsing with PBS, and backpack attached macrophages were detached 
from the glass slide using melibiose. The released cells with backpacks were seeded onto a 
slide and examined by confocal microscopy. The functionalization protocol yielded 80% 
conjugation. Noteworthy, backpacks did not affect macrophage viability (Supplemental Fig. 
4).
A preliminary in vitro test was carried out to show whether cell backpacks were able to cross 
a cell monolayer. Backpacks alone and those attached to macrophages were incubated in a 
transwell plate containing a cell monolayer of mouse brain endothelial cells (bEnd.3), and 
Klyachko et al. Page 3













chemoattractant, macrophage chemotactic factor-1 (MCP-1) (150 ng/ml, R&D Systems) that 
was placed into the lower chamber [19]. Following incubation at 37 °C in a shaker, the 
bEnd.3 inserts were removed, placed in 24-well plates with fresh media, and centrifuged to 
pellet the migrating cells to the plate's bottom chamber (See online methods for details). As 
shown in Fig. 3, some backpacks were able to cross the cell monolayer in vitro, but 
significantly more could do so when attached to macrophages (Fig. 3A), meaning that the 
macrophages can work by facilitating the passage of backpacks through the BBB. The 
macrophages themselves are able to cross the cell monolayer in vitro and the added bulk 
from the cell backpacks slightly slows their transfer (Fig. 3B).
2.3. Recruitment of macrophages with the attached backpacks to the brain in LPS-
intoxicated mice
To determine whether the macrophages were capable of carrying the cell backpacks across 
the blood-brain barrier in vivo, we used C57/BL mice with LPS-induced brain inflammation 
as described earlier [23]. Twenty-four hours later, freshly prepared macrophage-backpack 
conjugates were administered intravenously (5 × 106 cells/mouse in 100 µl). Fourteen hours 
later, mice were sacrificed, perfused, brains were sectioned, and examined by confocal 
microscopy. LPS-intoxicated mice injected with backpacks alone (no macrophages) were 
used as a control group. As shown in Fig. 4A, many macrophage aggregates (green) can be 
seen all over the brain. Noteworthy, only macrophage aggregates can be observed in that 
image (single macrophages or single backpacks cannot be observed). To better visualize 
whether backpacks were present in the brain, zoomed in images (40×) were acquired. Fig. 
4C–E shows co-localization of fluorescently-labeled macrophages (green) and backpacks 
(red) manifested in white staining (shown by arrows). These images confirmed that 
macrophages delivered considerable amounts of backpacks to the inflamed brain. 
Noteworthy, loading macrophages with backpacks slightly slow down their transport to the 
brain (Supplemental Fig. 5) that was consistent with the results of in vitro transport 
experiment (Fig. 3B). No fluorescence was found in the inflamed brain when backpacks 
were injected alone (without cells) indicating that systemically administered macrophages 
accomplished transport of backpacks cross the BBB in the presence of brain inflammation 
(Fig. 4B).
2.4. Use of cell backpacks for drug delivery across the BBB
The ability of the macrophages to facilitate delivery of the cell backpacks across the BBB, 
suggests a new versatile platform for drug delivery. As described in Fig. 1, the backpacks 
were assembled to contain the enzyme catalase because of its antioxidant properties and 
potential for treating brain inflammation [24–27]. Although the payload region in this case 
was customized for catalase assembly, the versatility of LbL assembly enables the loading of 
a variety of therapeutics ranging from small molecules, to peptides and proteins [16,28–33]. 
With our catalase-loaded cell backpacks, we characterized their physical properties and 
biochemical activity. After film assembly, the total thickness (prior to release from the 
substrate) was ~600 nm. Separate measurements of the film growth of (CAT9.0/PAH9.0) 
films (Supplemental Fig. 1) reveal that this payload region is roughly 250 nm, indicating that 
a large fraction (~43%) of the backpack contains catalase. Furthermore, the maximal amount 
of catalase is loaded at 30 bilayers (Supplemental Fig. 1B). We quantified the activity of 
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catalase in the cell backpacks via decomposition of hydrogen peroxide and found 2.3 µU/
cell backpack.
Fig. 5A shows that catalase freely dissolved in solution is readily deactivated when exposed 
to protease (~80% deactivation). Over 50% deactivation of catalase is also observed when 
(PAH9.0/CAT9.0) 30.5 films, representing the payload region, were incubated with protease. 
Interestingly, catalase contained in the backpacks is protected against protease degradation, 
exhibiting only ~40% deactivation. This fact can be explained by the presence of the cell-
adhesive region placed on the top of the catalase containing payload region. Past works 
demonstrate that LbL films deposited onto catalase-contained nanoparticles are able to 
inhibit molecules larger than 5 nm from penetrating through the multilayer, thereby 
protecting the catalase against proteolysis [34,35]. In this case, the top of the payload is 
protected by the adhesive region, but the sides of the backpacks expose some of the catalase 
that are packed inside the backpacks, making them available to protease attack. To test this 
hypothesis we assembled the full backpack structure [(BSM/JAC)60 + (PAH/MNP)10.0 + 
(PAH/CAT)30 + (PAA/PAH-biotin)10] on a non-patterned slide. Non-patterned backpack 
films showed improved protection of the payload (catalase) (Supplemental Fig. 6).
The release of catalase from pre-loaded cell backpacks was evaluated by enzymatic activity 
using dialysis membranes with a cut off 2000 KDa (Fig. 5B–C). A prolonged and sustained 
release was recorded; less than 50% of catalase was released over 18 h (Fig. 5B). 
Furthermore, when incorporated into backpacks, catalase was stable over 42 days (Fig. 5C); 
about 60% and 75% of the catalase activity in backpacks was retained when stored at 4 °C 
and −20 °C, respectively.
Noteworthy, the attachment of the backpacks to the cell-carriers did not result in their 
activation and excessive production of Reactive Oxygen Species (ROS) into the media 
(Supplemental Fig. 7).
2.5. Modulation of ROS released by activated microglia
To assess the antioxidant capacity of the catalase-loaded cell backpacks on microglial ROS 
production, macrophages with attached empty or catalase-loaded backpacks were incubated 
for 2 h in Krebs-Ringer buffer, and the reluctant supernatant was then collected and added to 
tumor necrosis factor (TNF-α)-stimulated microglial cells (200 ng/ml). The catalase in the 
supernatants collected from the catalase-loaded macrophages decomposed hydrogen 
peroxide produced by activated microglia (Fig. 6). Furthermore, the supernatants collected 
from empty cell backpacks, or non-loaded macrophages (Supplemental Fig. 8) had little, if 
any effect on hydrogen peroxide levels. Altogether, this study suggests that cells with 
catalase-loaded patches can attenuate oxidative stress resulting from activation of microglia.
3. Discussion
We report here the use of a macrophage-based formulation that might serve as treatment of 
neurodegenerative disorders, that include Parkinson's and Alzheimer diseases (PD and AD), 
HIV-associated neurocognitive disorders [37,38], and stroke [39,40]. It was reported that 
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these disorders, are accompanied with brain inflammation [41] and excessive production of 
free radicals that are toxic to neurons [42–45].
The tendency of monocytes and macrophages to migrate to sites of inflammation makes 
them attractive candidates for use as vehicles to attenuate inflammation. We demonstrated 
earlier that systemically administered inflammatory cells home to regions of inflammation 
and neurodegeneration, accumulate at therapeutically relevant numbers, and deliver 
therapeutics to the inflamed mouse brain [26,27,46–49]. This property allow efficient 
disease treatment along with reductions in tissue toxicities and side effects.
Backpacks loaded with different types of cargo (e.g. enzymes, antibiotics, anti-
inflammatories, anticancer drugs) can be conjugated to the surface of living cells (e.g. 
macrophages, lymphocytes, monocytes). The cell-backpack conjugate is then used as 
targeted drug-delivery system, since cell motility enables a targeted delivery that would not 
otherwise be achievable. Most importantly, attachment to macrophages enables the non-
invasive delivery of drugs to sites of inflammation, especially across the BBB, a significant 
obstacle to drug treatment by traditional means such as systemic drugs. Furthermore, we 
demonstrated here that attachment of cell backpacks to macrophages did not alter their 
major functions, including adherence capability, or cell activation. However, it may affect 
trafficking backpack-laden macrophages to the brain. Indeed, micropatches conjugated to 
the cell-carriers may slow-down macrophage transport across the BBB due to the increased 
size. Nevertheless, the possibility of loading large amounts of therapeutics into the 
micropatches, along with sustained release and minimized drug exposure to the cell-carriers, 
provides a remarkable advantage over common strategies. Indeed, we confirmed that 
significant amount of backpack-laden macrophages were able to target and deliver cell 
backpacks to the inflamed brain tissues. We suggest that the large contact area between a 
backpack and cell-carrier, and strong antibody-mediated binding to macrophages result in 
extraordinary stability of the construct in vivo that allows macrophages efficiently penetrate 
across the cell monolayers without losing their cargo.
We utilize in this study one of the most potent antioxidants in nature, catalase. The means 
for successful therapy of such disorders by attenuating free radicals production has met with 
limited success based, in part, due to inefficient enzyme delivery to the affected brain 
regions and across the BBB [50]. As such, an efficient delivery of catalase to the brain may 
be instrumental for PD therapy. To accomplish macrophage-mediated delivery to the brain, 
we developed a method where catalase was incorporated into cell backpacks without losing 
its enzymatic activity, and then drug-loaded patches were attached to the cell-carriers. 
Catalase incorporated into backpacks reduced neuroinflammatory responses in vitro 
providing a translational link of these formulations to the clinic. Furthermore, we 
demonstrated that macrophages with attached backpacks facilitated their transport to the 
inflamed brain in a mouse model of LPS-induced encephalitis. We suggest that engaging 
natural immune cells such as monocyte/macrophages as drug carriers provides a new 
perspective for a range of different neuroinflammatory and neurodegenerative diseases.
Using the inflammation as a driving force for targeted cell-mediated drug delivery is a very 
attractive approach. Nevertheless, one should take into consideration that any other 
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inflammatory processes in addition to the CNS inflammation may divert cell-carriers from 
the brain and decrease the therapeutic efficacy of cell-incorporated drug formulations. In 
clinic, if this is the case, a short pre-treatment of a patient with antibiotics should be carried 
out before the cell-based therapy is initiated.
4. Online methods
4.1. Materials
CAT: Catalase from bovine liver was purchased from Calbiochem (San Diego, CA), or from 
Sigma-Aldrich; PAH: Poly(allylamine hydrochloride), MW 120–200 g/mol (for the 
magnetic region). PAA: Poly(acrylic acid) MW 200,000 g/mol 25% soln. In water 
(Polysciences). MNP: Magnetic nanoparticles, EMG 705 from FerroTec, 10 nm in diameter 
particles. BSM: bovine submaxillary mucin (Sigma). JAC: lectin jacalin (Vector 
Laboratories). TRIS: Tris(hydroxymethyl)aminomethane (Sigma-Aldrich). NHS-Biotin: (+)-
Biotin N-hydroxysuccinimide ester (Sigma Aldrich). Positive photoresist S1813, 
MicroChem. Developer MF319. Micro BCA reagent (Thermo Fisher). 6-
Hydroxydophamine (6-OHDA), lipopolysaccharides (LPS), and Triton X-100 were from 
Sigma-Aldrich (St. Louis, MO, USA). Interferon gamma (INF-γ) was purchased from 
Peprotech Inc. (RockyHill, NJ).
4.2. Cellular backpacks fabrication
Backpacks were fabricated according to previous works [12,14]. Briefly, a clean glass slide 
was spin-coated with a photoresist (S1813 positive photoresist, MicroChem) layer. Next, the 
photoresist is soft-baked to evaporate the solvent and then placed in a custom-made device 
that holds a photomask and a UV lamp. The parts exposed to the UV lamp are then removed 
by soaking the glass slide in a developer (MF319) solution, which will generate a photo-
patterned slide. The patterned substrate contains circular areas of 7 µm diameter holes and 
15 µm edge-to-edge spacing. The next step is to conformally coat the patterned slide with 
the desired multilayer films using LbL, and then dissolve the remaining parts of the 
photoresist to leave the backpacks attached to the glass slide.
4.3. Multilayer thin films
The backpacks are comprised of 4 different regions. The first region deposited is called the 
releasable region and is composed of (BSM7.4/JAC7.4)60 [18]. Next, a magnetic region of 
(PAH3/MNP4)10.5 is deposited on the top of the releasable region to add rigidity [51]. The 
payload region is assembled on the top of the magnetic region and is comprised of (CAT9.0/
PAH9.0)30. Both PAH (1 mg/mL) and CAT (0.5 mg/mL) were dissolved in TRIS buffer 20 
mM pH 9.0. Deposition times for both CAT and PAH was of 10 min, followed by two rinse 
steps of 2 and 1 min each. Rinse steps were performed using TRIS buffer (20 mM, pH 9.0). 
Details on catalase multilayer film choice will be published in a separate manuscript. Lastly, 
the samples were topped with the adhesive region, composed of (PAA4.0/PAH-biotin4.0)10 
[52]. Note that all the solutions were freshly prepared and used on the same day.
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Samples 50 µg/mL NeutrAvidin Dylight 633 in pH 7.4 PBS buffer for 1 h at 4 °C. Glass 
slides are rinsed three times in PBS. Backpacks are then incubated with biotinylated 
antibody (50 µg/mL) diluted with PBS buffer (pH 7.4) for 1 h at room temperature in pH 7.4 
PBS buffer, followed by three rinse steps to remove the non-reacted antibody.
4.5. Release of cell-backpacks conjugates directly from the glass slide
Cell incubation protocol example can be found in work published by our group [16,52]. 
Briefly, the slide is cut and placed in the bottom of a well in a 6-well plate or a small Petri 
dish. 2 mL of cells suspended in appropriate media (~106 cells/mL) are pipetted onto the 
surface. The entire plate is agitated for 15 min at 37 °C, followed by 37 °C incubation for 15 
min, and this cycle is repeated identically once more. The glass slide, now containing cells 
attached to surface-bound patches, is removed and gently shaken for ~15 s upside down in 
37 °C PBS to remove all cells not attached to a patch.
In this case, to release the cell-backpacks, 1 mL of 100 mM of melibiose in PBS was added 
to the top of the glass slide and incubated for 1 h at 37 °C. These solutions were then 
pipetted up and down to release the cell-backpacks from the glass slide. Additionally a cell 
scraper is used to help remove the cell-backpack conjugates from the glass slide.
4.6. Backpacks thickness
Backpacks thicknesses were measured using a profilometer (Tecan).
4.7. Backpacks and PAH/CAT films activity
Catalase activity inside backpacks and PAH/CAT films was assayed by incubating the 
samples with hydrogen peroxide solution. A piece of ~1 cm2 of a glass slide containing the 
backpacks or the PAH/CAT films was placed inside a 20 mL glass vial containing a 3 mL of 
a 15 mmol solution of H2O2 diluted in PBS. Samples were agitated (150 rpm) for 2 min and 
then most of the solution of H2O2 was transferred to a quartz cuvette (optical path length of 
1 cm) and the absorbance read at 240 nm. The solution was then placed back inside the 
original vial and re-analyzed every 2 min until 4 or 5 time points were collected. The slope 
of the consumption of H2O2 was then used to calculate the activity of the enzyme (U/area), 
by using the following equation [53]. The test was run in triplicate. The areas of glass slide 
pieces were measured for normalization.
(1)
where dA/dt is the change in the absorbance with respect to time, V is the total volume of 
hydrogen peroxide and PBS used, A is the area of the glass slide piece, b is the optical path 
length of the cuvette and Ɛ is the extinction coefficient for the hydrogen peroxide. The 
extinction coefficient is calculated from the slope of a H2O2 calibration curve, in this case Ɛ 
was equal to 43.6 M−1cm−1. The areas of each slide were normalized to plot the average 
activity of the slides over time, and the percent of the activity remaining relative to the 
controls.
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4.8. Protease challenge test
Samples were cut from the slide into approximately 1 cm [2] pieces and placed in 20 mL 
glass vials. The areas were measured for normalization. Two of the pieces of backpacks 
samples were incubated in 3 mL of protease solution (3.3 mg/mL in PBS), and one sample 
was used as a control (incubated in 3 mL of PBS). Samples were incubated in protease 
solution (37 °C) for 30 min, 1 h, 1 h30 min, and 2 h. Once the desired incubation time was 
completed, samples were rinsed thoroughly in PBS solution to remove excess of protease, 
and then placed in vials containing 5mL of hydrogen peroxide solution (15 mM in PBS). For 
time point zero (no protease incubation, control) samples were immediately tested after 
adding hydrogen peroxide solution. Once in a hydrogen peroxide solution, absorbance decay 
of hydrogen peroxide was measured overtime at 240 nm, by measuring the absorbance of 
each sample about every 2 min for about 10 min, recording the time, sample, and 
absorbance. To measure the absorbance, solution from the glass vial was carefully poured 
into a quartz cuvette, and then poured back into the vial after each reading. Samples were 
agitated at 150 rpm between readings. Absorbance values were plotted versus time to find 
the slope. This procedure allowed calculating the activity of the pieces of slide using 
Equation (1).
4.9. Catalase release from backpacks
CAT backpacks were incubated in PBS solution, at 37 °C and samples of the supernatant 
were collected over time (up to 72 h). Micro BCA analyses were performed in order to look 
for catalase in solution.
4.10. Cell culture
A human colon epithelium cell line, Caco-2, (ATCC CCL-17), mouse transformed 
endothelium cell line, b.End 3 (ATCC® CRL-2299)), and mouse macrophage cell line RAW 
264.7 (ATCC TIB-71) were cultured in Dulbecco's Modified Eagle's Media (DMEM, 
Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 10 mM HEPES and 
penicillin/streptomycin.
To obtain bone marrow-derived macrophages (BMM), cells were extracted from femurs of 
C57/BL male mice [54] and cultured for 12–14 days in DMEM medium (Invitrogen, 
Carlsbad, CA) supplemented with 1000 U/mL macrophage colony-stimulating factor 
(MCSF).
4.11. Loading macrophages with cell backpacks
A half of glass slide with cell backpacks attached was placed into 6-well plate, and 
supplemented with 500 µl NeutrAvidin Dylight 550 (50 µg/mL final concentration) in pH 
7.4 PBS buffer for 1 h at 4 °C. Then, the glass slide was rinsed 3× in PBS, and backpacks 
were incubated with biotinylated CD11b antibody (50 µg/mL) diluted with PBS buffer (pH 
7.4) for 1 h at room temperature in pH 7.4 PBS buffer. Following incubation, the glass slide 
was rinsed 3× with PBS to remove the non-reacted antibody, and DIO-labeled Raw 264.7 
macrophages (green) suspended in 2 mL media (~2 × 106 cells/mL) were pipetted onto the 
surface of the glass slide with backpacks and covered with foil. The entire plate was agitated 
for 15 min at 37 °C, followed by 37 °C incubation for 15 min, and this cycle was repeated 
Klyachko et al. Page 9













identically once more. Then, the glass slide, containing cells attached to surface-bound 
patches was washed 3× with media to remove all cells not attached to a patch, and red 
backpacks on the slide with green cells attached were examined with fluorescent microscope 
(Supplemental Fig. 4). 1 mL of 100 mM of melibiose in PBS was added to the plate on top 
of the glass slide and incubated for 1 h at 37 °C in the incubator to detach cell-carriers with 
backpacks from the glass slide. Then, the cells were detached by pipetting them up and 
down and utilized in subsequent studies.
4.12. Antioxidant activity measurements
Catalytic activity of catalase alone or incorporated into call patches was measured by two 
methods: spectrophotometry and Amplex Red assay. In cell-free system, catalase activity 
was measured by hydrogen peroxide decomposition method as described earlier [36]. The 
initial activity was 38,000 U/mg protein for catalase. The concentration dependence of 
enzymatic activity as well as catalase stability was studied in a range of 1.7–35.2 mM 
hydrogen peroxide, and expressed in residual activity vs. Initial activity of catalase in the 
backpacks.
The decomposition of ROS by catalase released from backpacks in pre-activated 
macrophages was evaluated by CellROX Green Reagent fluorescence assay (Molecular 
probes) as described earlier [55]. Briefly, various doses of catalase-loaded cell backpacks 
(1.3 × 106 backpacks/ml; 1.3 × 105 backpacks/ml; 1.3 × 104 backpacks/ml; or 1.3 × 103 
backpacks/ml) were added to activated macrophages for 18 h. Following incubation, the 
supernatants were supplemented with CellROX Green Reagent (stock solution was diluted 
in assay buffer 25 times, and 50 µl of working solution was added to the fresh plate with 50 
µl media from the cells for 1 h). The decomposition of free radicals by catalase released 
from backpacks was measured by fluorescence at λex/λem = 490 nm/520 nm.
4.13. Macrophage adherence and migratory activities
It is known that immune cells utilize various integrins, in particular α-4 integrin to passage 
into the central nervous system (CNS) [56]. Therefore, we investigated whether attachment 
of catalase-loaded patches affect macrophage ability to adhere and migrate in vitro model of 
BBB as described earlier [57]. Macrophages were incubated with backpacks loaded with 
catalase. After the incubation macrophages were stained with phycoerythrin (PE)-
conjugated anti-CD49d antibodies; and PE-Cy5-conjugated nonspecific antibodies as 
isotype control. Migratory activities were investigated in two in vitro models of BBB: 
confluent monolayers of bEnd 3 and Caco-2 cells that were grown on polycarbonate inserts 
[57]. The procedure was described in19. FITC-labeled Raw 264.7 macrophages (green) were 
loaded with fluorescently-labeled backpacks (red) backpacks as described above. Cell-free 
backpacks were used as a control. We utilized macrophage chemotactic factor-1 (MCP-1) as 
a chemoattractant [19]. Following the incubation at several times (1 h, 4 h, and 14 h) at 
37 °C in a shaker, the cell inserts were removed, and centrifuged for 10 min at 400g to pellet 
the migrating cells with cell backpacks or backpacks alone to the plate's bottom chamber. 
For adherence studies, BBB monolayers were grown on 24-well plates as described [57]. 
Macrophages labeled with Alexa Fluor 680, were loaded with backpacks, and added to BBB 
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cell monolayers. Non-loaded BMM were used as a control. The amount of Alexa Fluor-
labeled macrophages was measured determined as described in Ref. [58].
4.14. Animals
Male C57/BL mice (Charles River Laboratories, USA) 8 weeks of age were used in 
experiments demonstrating brain targeting by macrophages with cell backpacks. The 
animals were kept five per cage with an air filter cover under light- (12-h light/dark cycle) 
and temperature-controlled (22 ± 1 °C) environment. All manipulations with the animals 
were performed under a sterilized laminar hood. Food and water were given ad libitum. The 
animals were treated in accordance to the Principles of Animal Care outlined by National 
Institutes of Health and approved by the Institutional Animal Care and Use Committee of 
the University of North Carolina at Chapel Hill.
4.15. Confocal microscopy
To utilize confocal imaging, macrophages were labeled with a fluorescent dye DiO [27]. For 
in vitro investigations, DiO-labeled Raw 264.7 macrophages with fluorescently-labeled back 
packs attached were seeded to the chamber slides and examined by confocal microscope. 
For in vivo investigations, C57/BL mice with brain inflammation caused by LPS intracranial 
injections (10 µg LPS in 0.9% NaCl with 0.02% ascorbic acid, flow rate of 0.1 µL/min into 
the striatum (AP: +0.5; L: −2.0 and DV: −3.0 mm)) were used. Twenty four hours later, 
macrophages (green) with backpacks (red) attached were systemically injected into LPS-
intoxicated mice (5 mice/group, three independent experiments). Fourteen hours later, mice 
were sacrificed, perfused according to standard protocol; brain slides were sectioned, and 
examined by confocal fluorescence microscopy. Mice injected with cell-free backpacks were 
used as a control group (5 mice/group). To examine effect of cell patches attachment to 
macrophages, another control group of mice was injected with non-loaded macrophages.
4.16. Statistical analysis
To investigate for statistical significance of the obtained results, a one-way ANOVA with 
multiple comparisons using GraphPad Prism 6.0 was used. A significance level was chosen 
at a minimum p value of 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scheme showing the catalase containing backpack structure. From bottom to top: Release 
region is composed of 60 bilayers of bovine submaxillary mucin (BSM) and lectin jacalin 
(JAC); Magnetic region made of 10.5 bilayers of poly(allylamine hydrochloride) (PAH) and 
magnetic nanoparticles (MNP); Payload region containing 30 bilayers of PAH and catalase 
from bovine liver (CAT); Cell attachment region comprised of 10 bilayers of poly(acrylic 
aid) (PAA) and biotinylated PAH (PAH-biotin). Backpacks are topped with CD11b 
antibodies for macrophage conjugation.
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Macrophages with attached backpacks in vitro. A: 40× magnification; B: 2× zoom 63× 
magnification. The bar: 20 µM. Macrophage nuclei are stained in blue (DAPI); backpacks 
are stained in red (Neutravidin Dylight 550); macrophages are stained with DiO (green). 
(For interpretation of the references to colour in this figure legend, the reader is referred to 
the web version of this article.)
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In vitro assay of the translocation of macrophages, cell-backpacks, and macrophage-
backpack conjugates across cell monolayers. The cartoon illustrates the ability for 
backpacks alone (upper left scheme), macrophage-backpack conjugates (center scheme) or 
macrophages alone (upper right scheme) to cross a cell monolayer in vitro. A) Macrophage-
mediated transport of backpacks across the BBB in vitro; B) Macrophage transfer across the 
BBB in vitro. A: Fluorescently-labeled backpacks loaded onto non-labeled macrophages 
(red bars) or cell-free backpacks (black bars) were added to a donor chamber of bEnd.3 cell 
monolayers seeded onto inserts. B: Fluorescently- labeled macrophages with attached 
backpacks (green bars) or non-loaded “free” cells (black bars) were added to a donor 
chamber of bEnd.3 cell monolayers seeded onto inserts. Following different time points, the 
media from the receiver chamber was collected and examined for the amount of backpacks 
(A) or macrophages (B) transferred across the cell monolayers. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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Fig. 4. Recruitment of macrophages with the attached backpacks to the brain in LPS-intoxicated 
mice
Fluorescently-labeled DiO-macrophages (green, 2 × 106 cells/ml) loaded with fluorescently-
labeled backpacks (red, NeutrAvidin 550) attached. Cell-backpacks (5 × 106 cells/mouse in 
100 µl) were injected into C57/BL mice (5 mice/group) with brain inflammation (A, C–E). 
Fourteen hours later, mice were sacrificed, and brain slides were examined by confocal 
microscopy (A: whole brain, B–E: 40× magnification). LPS-intoxicated mice injected with 
backpacks alone (no cell-carriers, 5 mice/group) were used as a control group (B). Co-
localization of fluorescently-labeled macrophages (green, C) and backpacks (red, D) 
manifested in yellow staining (E) confirmed that macrophages delivered considerable 
amount of backpacks to the inflamed brain (shown by arrows). No fluorescence was found 
in the inflamed brain when backpacks were injected alone (without cell-carriers, B) 
indicating that systemically administered macrophages facilitated transport of backpacks 
across the BBB in the presence of brain inflammation. The representative images from three 
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independent experiments. The bar: 20 µm. (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.)
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Characterization of catalase incorporated into cell backpacks. A) Protease challenge test: 
free-standing catalase in solution, payload region films (PAH9.0/CAT9.0)30.5, and catalase 
containing backpacks had their activity measured before and after incubated in PBS 
(control) or in protease solution for 2 h, 37 °C. Remaining of activity (%) was calculated 
relative to time zero incubation time (initial activity). B) Activity of catalase released from 
backpacks was measured using hydrogen peroxide decomposition by monitoring the change 
in absorbance at 240 nm (the extinction coefficient of H2O2 is 44 M−1cm−1) [36]. C) 
Loading of catalase into backpacks increased stability of the enzyme against a mixture of 
proteinases (trypsin and pronase). Contrary to the free catalase (white bars) that was 
completely inactivated by proteinases after 2 h, backpack-incorporated catalase remained 
active for more than 72 h.
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Fig. 6. Antioxidant activity of catalase-loaded backpacks in activated macrophages
RAW 264.7 macrophages were activated with 100 µg/ml LPS overnight. 24 h later, various 
amount of catalase-loaded backpacks were added to the cells and the levels of ROS in call 
were measured. Catalase in higher doses of backpacks efficiently decreased ROS produced 
by activated macrophages to the levels in non-activated cells.
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